Sign up USA
Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

ANGLE plc | Faron Pharmaceuticals Ltd | Alliance Pharma plc | Clinigen Group PLC | Avacta Group Plc

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.


This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.


The event is not suitable for people pursuing commercial opportunities.

Alliance Pharma plc

RSS Portfolio


Alliance is an international publicly owned pharmaceutical group listed on AIM, part of the London Stock Exchange. It was founded in 1998 and has its headquarters in the UK.

Alliance's principal activities are the acquisition and licensing of mature pharmaceutical products and the marketing of those products. Its manufacturing, storage, logistics and sales forces are controlled by Alliance but outsourced to leading specialist organisations in these fields.

Our expertise lies in the acquisition and licensing of pharmaceutical and healthcare products and delivering these to patients. We look carefully for certain criteria in these products and select for a blend of underlying sales stability and growth potential.

Market: AIM
52-week High/Low: 71.00p / 46.00p
Market Cap: 320.17M

View full company profile


RSS Portfolio


ANGLE plc is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health.

ANGLE plc’s lead product is the Parsortix cell separation system, which can capture very rare cells from blood. This includes circulating tumor cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient’s cancer for personalised cancer care.

ANGLE plc has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe. The FDA approval process is underway for the clinical market in the US.

Market: AIM
52-week High/Low: 80.00p / 32.27p
Market Cap: 55.03M

View full company profile

Avacta Group Plc

RSS Portfolio


Avacta’s principal focus is on its proprietary Affimer® platform, a novel engineered alternative to antibodies that has wide application in diagnostics, therapeutics and research.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer proteins, which can be quickly generated to bind with high specificity and affinity to a wide range of targets, have been designed to address these negative performance issues. 

Avacta has a pre-clinical drug development programme with a primary focus on immuno-oncology as well as partnered development programmes. Avacta is also commercialising non-therapeutic Affimer reagents through licensing to developers of research tools and diagnostics.

Market: AIM
52-week High/Low: 98.00p / 37.00p
Market Cap: 26.21M

View full company profile

Clinigen Group PLC

RSS Portfolio


Clinigen is a rapidly-growing specialty pharmaceutical and service company with a unique business model dedicated to delivering the right medicine to the right patient at the right time to improve the quality of people's lives around the world.

To achieve our aim, we have built a group of complementary businesses which can operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, whenever they are needed throughout the production lifecycle. Through four businesses, Clinigen Clinical Trial Services, Idis Managed Access, Idis Global Access and Clinigen Specialty Pharmaceuticals, we provide patient access to our own and other pharmaceutical companies' products, whether to meet unmet medical needs or for use in clinical trials.

Clinigen is traded in the NEX Exchange HERE

Market: AIM
52-week High/Low: 1,187.00p / 754.00p
Market Cap: 11.05M

View full company profile

Faron Pharmaceuticals Ltd

RSS Portfolio


Faron Pharmaceuticals is a clinical stage drug discovery and development company based in Turku, Finland. Faron has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. Implementing the strategy of creating a novel treatment for significant unmet medical needs, Faron has now entered into a pan-European pivotal Phase III study with its lead candidate Traumakine®, which targets the treatment of Acute Respiratory Distress Syndrome (ARDS). Currently there is no available drug treatment for ARDS, an orphan lung disease coupled with a reported mortality rate of approximately 30 to 45%. Although ARDS is not common, there are about 170 000 patients annually in Europe and nearly 200 000 in the US.

Market: AIM
52-week High/Low: 900.00p / 500.00p
Market Cap: 255.98M

View full company profile
Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use